<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862835</url>
  </required_header>
  <id_info>
    <org_study_id>13-000047</org_study_id>
    <nct_id>NCT01862835</nct_id>
  </id_info>
  <brief_title>Impact of Estradiol Addback</brief_title>
  <official_title>Impact of Estradiol Addback on Somatostatin Rebound in Older Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repletion of testosterone (T) in older men drives Growth Hormone secretion after its
      aromatization to estradiol (E2) by potentiating endogenous GH drive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic concentrations of Te, E2, GH, Insulin-like Growth Factor-I and IGFBP-3 decline in
      healthy aging men. Relative sex-steroid deprivation accentuates GH and IGF-I depletion,
      since Te stimulates GH and IGF-I production in older men, hypogonadal males of all ages, and
      patients undergoing (genotypic female-to-male) gender reassignment. Tamoxifen blocks this
      effect of Te, suggesting involvement of E2  in GH's stimulation in men. E2 per se stimulates
      GH secretion in women. Because Te is converted to E2 by aromatization in the body, we
      postulate that E2 is the active moiety in men also. Moreover, we hypothesize that the
      decline of E2 in older men contributes to the fall in GH output. This has never been tested.
         From a clinical vantage, understanding the mechanistic basis of Te's drive of the
      somatotropic axis is especially relevant in boys with pubertal failure, adults with primary
      hypogonadism and men with aging-related hypoandrogenemia. In relation to aging in the male,
      testosterone and E2 bioavailabilities fall by 35-50% in the eighth compared with third
      decade of life. From a medical perspective, aging is accompanied by progressive osteopenia,
      sarcopenia and intra-abdominal obesity. These adverse outcomes are remediable by short-term
      replacement with Te and/or recombinant GH, thus linking GH/Te/E2 availability with key
      body-compositional features.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>BioStatistical Analysis</measure>
    <time_frame>Subjects will undergo 15-h overnight (2200 - 1300 h) fasting, 10-min blood sampling</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary analytical outcome is the summed mass of GH secreted in pulses over the 15 h of overnight blood sampling. The outcome measure is relevant, since sex-steroid hormones and regulatory peptides uniquely control GH secretory-burst mass.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Normal Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Degarelix/Te/placebo/ placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>degarelix/Te/anastrozole/ placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>degarelix/Te/ anastrozole/E2 patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>degarelix/ placebo/placebo/no patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch  beginning on day 1 and changed every 3 days through day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <arm_group_label>Degarelix/Te/placebo/ placebo</arm_group_label>
    <arm_group_label>degarelix/Te/anastrozole/ placebo</arm_group_label>
    <arm_group_label>degarelix/Te/ anastrozole/E2 patch</arm_group_label>
    <arm_group_label>degarelix/ placebo/placebo/no patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <arm_group_label>Degarelix/Te/placebo/ placebo</arm_group_label>
    <arm_group_label>degarelix/Te/anastrozole/ placebo</arm_group_label>
    <arm_group_label>degarelix/Te/ anastrozole/E2 patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>degarelix/Te/anastrozole/ placebo</arm_group_label>
    <arm_group_label>degarelix/Te/ anastrozole/E2 patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen patch</intervention_name>
    <arm_group_label>degarelix/Te/ anastrozole/E2 patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  60 healthy men (ages 60 to 80 y);

          -  BMI 18-30 kg/m2

          -  Community dwelling; and voluntarily consenting

        Exclusion:

          -  Recent use of psychotropic or neuroactive drugs (within five biological half-live);

          -  Obesity (outside weight range above);

          -  Laboratory test results not deemed physician acceptable, cholesterol &gt;250,
             triglycerides &gt; 300, BUN &gt;30 or creatinine &gt; 1.5 mg/dL, liver functions tests twice
             upper limit of normal, electrolyte abnormality, anemia; hemoglobin &lt;12.0 gm/dL

          -  Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;

          -  Acute or chronic organ-system disease;

          -  Endocrinopathy, other than primary thyroidal failure receiving replacement; untreated
             osteoporosis

          -  Nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days
             of admission);

          -  Acute weight change (loss or gain of &gt; 2 kg in 6 weeks);

          -  Allergy to peanut oil (used in some injectable Te preparations)

          -  Unwillingness to provide written informed consent.

          -  PSA &gt; 4.0 ng/mL

          -  History or suspicion of prostatic disease (elevated PSA, indeterminate nodule or
             mass, obstructive uropathy.

          -  History of carcinoma (excluding localized basal cell carcinoma removed or surgically
             treated with no recurrence.

          -  History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep vein
             thrombophlebitis.

          -  History of CHF, cardiac arrhythmias, congential QT prolongation, and medications used
             to treat cardiac arrhythmias

          -  Gynecomastia &gt; 2 cm, untreated

          -  Untreated gallbladder disease

          -  History of smoking greater than one ppd.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Veldhuis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Yang, RN</last_name>
    <phone>507-255-1294</phone>
    <email>yang.rebecca@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Wigham, RN</last_name>
    <phone>507-293-1166</phone>
    <email>wigham.jean@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Yang, RN</last_name>
      <phone>507-255-1294</phone>
      <email>yang.rebecca@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Johannes D Veldhuis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Johannes D. Veldhuis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
